Barinthus Biotherapeutics (BRNS) Stock: Buy, Sell, or Hold?
BRNS - Barinthus Biotherapeutics plc American Depositary Shares
$0.74
-0.02 (-2.49%)
▼
5d:
+6.18%
30d:
+23.56%
90d:
+2.79%
WAIT
LOW Confidence
Analysis Updated: Sep 8, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When BRNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BRNS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BRNS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BRNS is currently trading at $0.74, which is considered extended relative to its 30-day fair value range of $0.58 to $0.72.
Technical Outlook: Technically, BRNS is showing sideways momentum. Immediate support is located at $0.64, while resistance sits at $0.82.
Market Sentiment: BRNS scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+710.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BRNS is showing sideways momentum. Immediate support is located at $0.64, while resistance sits at $0.82.
Market Sentiment: BRNS scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+710.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.58 -
$0.72
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 710.7% below Wall St target ($6.00)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.58 -
$0.72
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.64
Resistance Level
$0.82
Current Trend
Sideways
Technical data as of
Sep 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.65
Wall Street Target
$6.00
(+710.7%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: September 14, 2026 10:44 PM ET
Data refreshes hourly during market hours. Next update: 11:44 PM
Data refreshes hourly during market hours. Next update: 11:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BRNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 49 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 48 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 53 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 52 HOLD |
